Osteosarcoma is a type of cancer that originates from bone cells. Osteosarcoma of the bone is characterized by high grade tumor in the bone. High grade tumor variations include small-cell osteosarcoma, telangiectatic osteosarcoma, high-grade surface osteosarcoma, low-grade central osteosarcoma, and secondary osteosarcoma. Low-grade central osteosarcoma is found to be less aggressive with survival rate of around 90%. Low-grade central osteosarcoma is generally mistaken as fibrous dysplasia and considered as a rare variant of osteosarcoma. Low-grade central osteosarcoma may occur in long bones (femur, tibia, fibula, etc.) flat bones (ribs, mandible, etc.), hands and feet. Generally, biopsy is performed to diagnose low-grade central osteosarcoma and in some cases histological examination is needed. The recommended treatment for low-grade central osteosarcoma includes chemotherapy radiation and surgery. Etiology and exact cause of low-grade central osteosarcoma is unknown, but in most cases surgery is performed to remove the tumors.
Cancer is the second highest cause of death annually followed by cardiac complications. Discovering novel treatment options and drug regimens would be an opportunity offering immense growth possibilities in the cancer treatment market in the near future. Immunotherapy is a very active area of cancer research. Many scientists and doctors around the world are studying new ways to use immunotherapy to treat cancer. Government funding and initiatives supporting research and development in rare forms of cancer in developed countries is expected to support growth of the low-grade central osteosarcoma treatment market. Governments in developed countries such as the U.S. raise funds for cancer research to aid diagnosis and treatment. Clinical trials are also funded by governments to support companies in developing effective cancer immunotherapy drugs. Strategic collaborations with hospitals for cancer research studies on several hundred patients with a variety of cancer types has benefited the companies, enabling them to manufacture novel drugs for immunotherapy.
The global market for low-grade central osteosarcoma treatment is segmented based on treatment type and geography. In terms of treatment type, the market is categorized into chemotherapy, surgeries, and radiation therapy. According to American Cancer Society, some of the common chemotherapy agents which are prescribed in osteosarcoma chemotherapy includes Methotrexate, Doxorubicin, Ifosfamide, Cisplatin, Carboplatin, etc. In severe cases of metastatic low-grade central osteosarcoma, surgical procedures are performed to remove the tumor.
In terms of geography, the global low-grade central osteosarcoma treatment market is segmented into five key regions viz. North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to hold major share in the low-grade central osteosarcoma treatment market during the forecast period owing to the presence of developed infrastructure in the region and rising patient population. Europe is projected to hold the second largest market share during the forecast period owing to increasing discretionary funding for cancer research, and expanding cancer awareness programs by government and patient support programs. The market in the Asia Pacific region is expected to expand at a higher growth rate during the forecast period. Increase in health care spending and improving health care infrastructure in the region is expected to drive the overall cancer treatment market during the forecast period. Rising prevalence of liposarcoma, rise in medical tourism, and proactive educational campaigns to spread awareness among patients and health care professionals is set to propel the global low-grade central osteosarcoma treatment market in the near future.
The major players operating in the low-grade central osteosarcoma treatment market are Pfizer Inc., Eli Lilly and Company, Johnson & Johnson Services, Inc., Novartis AG, etc. The global low-grade central osteosarcoma treatment market is dominated only by few players such as Jonson & Jonson and Pfizer Inc. who operate globally.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Note : All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Transparency Market Research.